Details of the Drug

General Information of Drug (ID: DMX82DO)

Drug Name

Buformin

Synonyms

Buformin; 1-Butylbiguanide; Buformine; Butyldiguanide; Butylbiguanide; Butformin; Butylbiguanidum; Glybigid; 1-Butyldiguanide; Glybigidum; N-Butylbiguanide; Buformina; Buforminum; Buformine [INN-French]; Buforminum [INN-Latin]; Buformina [INN-Spanish]; Silubin; Adebit; BIGUANIDE, 1-BUTYL-; Buformin [USAN:INN]; W 37; Buformin HCl; Imidodicarbonimidic diamide, N-butyl-; Sindiatil; Panformin; Diabrin; Biforon; Andere; UNII-W2115E9C7B; Buformine HCl; N-butylimidodicarbonimidic diamide; DBV hydrochloride; H 224

Indication

Disease Entry	ICD 11	Status	REF
Type 2 diabetes	5A11	Approved	[1]

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

157.22

Topological Polar Surface Area

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 6.58 mL/min/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 4.62 hours [2]
Unbound Fraction: The unbound fraction of drug in plasma is 0.9% [2]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.84 L/kg [2]

Chemical Identifiers

Formula: C6H15N5
IUPAC Name: 2-butyl-1-(diaminomethylidene)guanidine
Canonical SMILES: CCCCN=C(N)N=C(N)N
InChI: InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)
InChIKey: XSEUMFJMFFMCIU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2468
ChEBI ID: CHEBI:3209
CAS Number: 692-13-7
DrugBank ID: DB04830
VARIDT ID: DR01669

Molecular Interaction Atlas of This Drug

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	National Center for Advancing Translational Science-Inxight: drug (W2115E9C7B)
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
5	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
6	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
7	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
8	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
9	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
10	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
11	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
12	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.